Renata PLC — Company profile

Pharmaceutical Preparations · Bangladesh

Last price 425.9 BDT (At close: Oct 29, 2026) · Market cap 48.85B

Latest research: Renata valuation report: fair value BDT 146–350 (Oct 2026) · Renata's FY2026 recovery is real, but a 10% return on equity supports BDT 146–350 a share (base 234)

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Technical report: trend, RSI, support and resistance, charts

Company profile

Renata PLC manufactures, markets, and distributes pharmaceuticals, animal health medicines, oncology-based, agro-based, poultry, and consumer products in Bangladesh and Portugal. The company offers generic products, including amantadine, clindamycin, clindamycin, colchicine, dipyridamole, escitalopram, fludrocortisone acetate, hydrocortisone, prednisolone, propylthiouracil, sertraline hydrochloride, terbinafine, and topiramate tablet and capsules. It also offers specialty products, such as SHK-024, an antidepressant, and SHK 007, to reduce toxicity in pediatrics. In addition, it provides animal health products. The company was formerly known as Pfizer Laboratories (Bangladesh) Limited and changed its name to Renata Limited in 1993. Renata PLC was incorporated in 1972 and is headquartered in Dhaka, Bangladesh.

Details

Key executives

Contact